Plocabulin

Star0

DB13137InvestigationalSmall molecule

PM060184 has been used in trials studying Solid Tumors.

Mechanism: Pharmacologically active on Tubulin
Curator reviewed
Formula / weight: C₃₁H₄₅N₃O₇ · 571.715 g/mol (avg)
Code names: J3.348.355D · PM-060184

Resolves to

Compound

UNII52Y8L60CR7CAS960210-99-5PubChem57788271

Structure

InChIKeyIEKGSKLKBICCHQ-BDOJOPHNSA-NSMILESCOC1=CC[C@H](OC1=O)[C@@H](C)\C=C(/C)\C=C/C=C\C(=O)N[C@H](C(=O)N\C=C/C[C@H](C\C=C/C)OC(N)=O)C(C)(C)C

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of Plocabulin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account